Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine.Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.
《肿瘤学年鉴》是欧洲肿瘤内科学会和日本肿瘤内科学会的期刊，提供快速有效的同行评审出版物，介绍与肿瘤学和精准医学相关的创新癌症治疗或转化工作。主要关注点包括：系统性抗癌治疗（特别关注分子靶向药物和新免疫疗法）、随机试验（包括阴性试验）、顶级指南和目前作为个性化医疗关键组成部分出现的新领域，如分子病理学、生物信息学、现代统计学和生物技术。如果放射治疗、外科和儿科手稿与上述领域之一有明显的相互作用或正在发生范式转变，则可以考虑这些手稿。
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
来源期刊：Annals of oncology : official journal of the European Society for Medical OncologyDOI：10.1093/annonc/mdz012
Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz394.019
Molecular pathology of tumors of the central nervous system
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz164
Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz253.016
Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz260.010
Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer.
来源期刊：Annals of oncology : official journal of the European Society for Medical OncologyDOI：10.1093/annonc/mdy546
Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz283.009
Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz426.007
Docetaxel for hormone-naive prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz248.001
Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz242.002
Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz338.079
The analysis of current treatment outcomes in melanoma patients with brain metastases
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz255.050
A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz252.032
Safety and efficacy of WX-0593 in ALK-positive or ROS1-positive non-small cell lung cancer
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz260.007
The effect of cortisol on methylation patterns in breast cancer cell lines
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz238.042
Safety profile of oral netupitant/palonosetron in hematopoietic stem cell transplantation recipients
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz276.013
Findings from a new specialist remote counselling service for neuroendocrine neoplasm (NEN) patients and family members
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz256.018
Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients: A prospective multicenter trial
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz265.013
Characterisation of growth hormone signal transduction in primary melanoma cell lines
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz238.028
Molecular profiling and prognostic significance of TP53 mutations in diffuse large b cell lymphoma: Identifying a high-risk subgroup
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz239.068
Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz446.014
JAK2 (V617F) positively regulates PD-L1 mRNA expression via STAT3/5 activation in MNP (PV and ET) patients
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz338.086
Gefitinib along with methotrexate as palliative therapy in PS 3 and above in metastatic squamous cell carcinoma head and neck cancer patients
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz261.015
Primary results from Japanese phase I study of pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz338.105
Drug selection by Narrative approach in patients with advanced gastric cancer -Paclitaxel or nab-Paclitaxel?-
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz338.037
Impact of β-catenin phosphorylation patterns on tumour control/progression in a prospective cervical cancer study (RAIDs)
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz413.017
Impact of donor lymphocyte infusion in relapsing myeloid neoplasms post allogeneic hematopoietic stem cell transplantation
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz251.023
PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
来源期刊：Annals of OncologyDOI：10.1093/ANNONC/MDZ283.046
Impact of cognitive-behavioral-therapy (CBT) on levels of anxiety, depression and distress in cancer patients (pts)
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz262.003
Combination treatment of astragalus membranaceus, dose-modified chemotherapy, and anti-PD1 checkpoint inhibitor for patients of advanced malignancy with initial cachexia or poor performance status: A single-institute experience
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz413.088
Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch colorectal cancer group
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz246.095
Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz418.011
Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz268.029
Re-introduction of T-VEC monotherapy in recurrent stage IIIB/C-IVM1a melanoma is effective
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz255.030
Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz264.014
Comparison between phase III randomized clinical trials and their preceeding phase II studies
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz263.011
Evaluating the role of clinical nurse specialist
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz277.014
Prevalance Geriatric in Hospitilized Cancer Patient
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz343.093
Scalp cooling with Cool Cap can palliate or avoid alopecia of adverse event by chemotherapy for breast cancer
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz338.046
High incidence and mortality of transitional cell carcinoma in Thai kidney transplant patients
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz425.002
Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz394.062
Differences in survival between right and left-sided colorectal cancer (CRC) in every stage, a CARESS-CCR group study
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz246.071
The tyrosine kinase inhibitor dasatinib blocks tumour growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz238.032
Oncologists’ consideration of health-related quality of life in clinical practice for immune-checkpoint inhibitors-treated patients: An online patients community research
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz449.005
A protein level signature of four selected genes associated with survival outcomes of patients with pancreatic ductal adenocarcinoma
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz247.025
Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz426.009
ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz250.071
N-terminal B-type natriuretic peptide (NT-proBNP) as an independed prognostic marker for patients with newly diagnosed multiple myeloma complicated by dialysis-dependent renal failure
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz251.021
Effective treatment with T-VEC monotherapy in stage IIIB/C-IVM1a melanoma of the head & neck region
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz255.029
An analysis of 30-day mortality after the last cycle of immune checkpoint inhibitors treatment
来源期刊：Annals of OncologyDOI：10.1093/annonc/mdz338.062
